TITLE

Herbal TB Immunotherapy Presented in Hong Kong

PUB. DATE
August 2011
SOURCE
Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article discusses Immune Network Ltd.'s discovery that a tablet version of its Imunoxel (Dzherelo) produced superior results in treating tuberculosis (TB) than its liquid form. These findings were presented by Ekomed at the 3rd Asia Pacific Region Conference of the International Union Against Tuberculosis and Lung Disease in Hong Kong, China in 2011. Immune also entered an agreement with Stirling Products Limited to make Immunoxel more affordable and accessible to patients requiring it.
ACCESSION #
63617960

 

Related Articles

  • Ethambutoli hydrochloridi compressi.  // International Pharmacopoeia: Third Edition;2003, p165 

    Description of the ethambutol hydrochloride tablets, which are included in the category of anti-tuberculosis drugs, is presented. It is mentioned that the ethambutol hydrochloride tablets are included in the current World Health Organization model list of essential drugs. The identity test and...

  • Segregated Delivery of Rifampicin and Isoniazid from Fixed Dose Combination Bilayer Tablets for the Treatment of Tuberculosis. Silva, A. M.; Abrahim-Vieira, B.; do Carmo, F. A.; do Amaral, L. H.; Silva, L. C.; Escudini, C. S.; Lopes, M. A.; Sousa, V. P.; Castro, H. C.; Veiga, F.; Rodrigues, C. R.; Ribeiro, A. J.; Cabral, L. M. // British Journal of Pharmaceutical Research;2014, Vol. 4 Issue 14, p1781 

    Aims: Develop an anti-tuberculosis (TB) Fixed Dose Combination (FDC) tablet containing an immediate release layer (IRL) composed of both rifampicin (RIF) and pyrazinamide (PYR) and a retarded release layer (RRL) comprised of isoniazid (INH) which would allow segregated delivery of RIF and INH....

  • FREE LIFE-SAVING MEDICINES FOR HALF A MILLION PATIENTS SUFFERING FROM TUBERCULOSIS.  // Indian Journal of Medical Sciences;Jan2004, Vol. 58 Issue 1, p38 

    Reports on the provision of free medication to tuberculosis patients following an agreement between the World Health Organization and Novartis Pharmaceuticals Corp. Donation of the drug to the Global Drug Facility; Reduction of mortality associated with the disease; Citation of the fixed dose...

  • Bedaquiline.  // AHFS Consumer Medication Information;Apr2018, p1 

    Bedaquiline is used along with at least three other medications to treat adults with multi-drug resistant tuberculosis (MDR-TB; a serious infection that affects the lungs and other parts of the body and that cannot be treated with at least two of the medications that are usually used to treat...

  • The Biggest Canine Loser. Luntz, Stephen // Australasian Science;Jul2007, Vol. 28 Issue 6, p13 

    The article features R-salbutamol, a weight-loss drug for dogs developed by Stirling Products Limited.

  • IMMUNE NETWORK HALTS PHASE I INTERACTION TRIAL.  // Worldwide Biotech;May2001, Vol. 13 Issue 5, p1 

    Announces the interruption of the Canadian Phase I drug interaction clinical study of Immune Network Ltd.

  • Evaluation and determinats of outcome of tuberculosis treatment. Maher, D.; Nunn, P. // Bulletin of the World Health Organization;1998, Vol. 76 Issue 3, p307 

    Presents information on the evaluated outcome of tuberculosis (TB) treatment. What accurate evaluation of treatment outcomes requires; Necessity of innovative approaches; Information on the national tuberculosis programme (NTP).

  • Tuberculosis. Zamula, E. // FDA Consumer;Mar1991, Vol. 25 Issue 2, p18 

    Examines how tuberculosis, once a top killer has declined dramatically in the first half of this century thanks to new drug treatments, improved hygiene, and better understanding of the disease. But now, the number of TB cases is beginning to creep up again. Airborne transmission; Testing for...

  • Supervised therapy cuts drug resistance, relapse in TB patients.  // Modern Medicine;Nov94, Vol. 62 Issue 11, p73 

    Presents an abstract of an article entitled `The Effect of Directly Observed Therapy on the Rates of Drug Resistance and Relapse in Tuberculosis,' by S.E. Weis, P.C. Slocum, F.X. Blais, et al. on the April 28, 1994 issue of the `New England Journal of Medicine.'

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics